Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group

New therapeutic strategies are needed for pediatric acute myeloid leukemia (AML) to reduce disease recurrence and treatment-related morbidity. The Children’s Oncology Group Phase III AAML1031 trial tested whether the addition of bortezomib to standard chemotherapy improves survival in pediatric pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Aplenc, Richard, Meshinchi, Soheil, Sung, Lillian, Alonzo, Todd, Choi, John, Fisher, Brian, Gerbing, Robert, Hirsch, Betsy, Horton, Terzah, Kahwash, Samir, Levine, John, Loken, Michael, Brodersen, Lisa, Pollard, Jessica, Raimondi, Susana, Kolb, Edward Anders, Gamis, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327649/
https://www.ncbi.nlm.nih.gov/pubmed/32029509
http://dx.doi.org/10.3324/haematol.2019.220962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327649/
https://www.ncbi.nlm.nih.gov/pubmed/32029509
http://dx.doi.org/10.3324/haematol.2019.220962

Ejemplares similares